Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (‘Questcorp’ or the ‘Company’) is excited to announce a strategic engagement with GRA Enterprises LLC, operating as the National Inflation Association (‘NIA’), to deliver a dynamic marketing and communications campaign aimed at boosting investor awareness and market visibility.

Under the terms of the agreement (the ‘NIA Agreement‘), which commences July 28, 2025, Questcorp will pay a one-time fee of US$30,000 for a three-month initial campaign, with the option for renewal. The NIA will leverage its expansive distribution channels-including targeted email lists, website features, and blog content-to highlight Questcorp’s compelling growth story and project developments.

‘As we continue advancing our highly prospective assets in British Columbia and Mexico, this partnership with NIA will allow us to connect with a broader investment audience and amplify our message at a pivotal time,’ said Saf Dhillon, Founding Director, President & CEO of Questcorp.

NIA, based in Mooresville, North Carolina, is an arm’s-length third party with a strong track record of investor communications for publicly traded companies. Questcorp confirms that no securities will be issued as part of this agreement and, to its knowledge, NIA does not currently own any equity or convertible instruments of the Company.

For more information about NIA: Contact ga@gerardadams.com or visit them at 112 Camp Lane, Mooresville, North Carolina, 28117.

About Questcorp Mining Inc.

Questcorp Mining Inc. is focused on the acquisition and exploration of precious and base metal projects across North America. The Company holds an option to acquire a 100% interest in the North Island Copper Property-covering 1,168 hectares on Vancouver Island, British Columbia-as well as the La Union Project in Sonora, Mexico, comprising 2,520 hectares. Both properties are subject to royalty obligations and represent high-potential targets for copper, silver, and gold exploration.

Contact Information

Forward-Looking Statements

This news release contains ‘forward-looking statements’ under applicable Canadian securities laws. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Readers are advised not to place undue reliance on forward-looking statements, which are based on current expectations and assumptions. The Company does not undertake to update or revise any forward-looking statements unless required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260142

Anteros Metals Inc. (CSE: ANT) (‘Anteros’ or the ‘Company’) is pleased to announce the commencement of a trenching and channel sampling program at its wholly-owned, road-accessible Havens Steady VMS Property (‘Havens Steady’ or the ‘Property’) in central Newfoundland. This milestone follows confirmation of a Junior Exploration Assistance (‘JEA’) grant, and receipt of a provincial permit authorizing ten mechanical trenches and four ground supported drill holes.

Work is now underway at the Main Mineralized Zone (‘MMZ’), where recent grab sampling confirmed high-grade lead-zinc-silver mineralization. Channel sampling of existing outcrop exposure will generate inaugural grade over width data for the MMZ zone, and will be followed by mechanized trenching to expose bedrock across key areas of the MMZ in addition to the highly-prospective northeastern extension area. The channel and trenching program will result in high-confidence targets slated to be drilled in 2025.

‘The start of trenching and channel sampling at the MMZ marks an important step in systematically advancing Havens Steady,’ said Trumbull Fisher, CEO of Anteros Metals. ‘With strong provincial support through the JEA program and multiple high-grade surface discoveries already in hand, we’re eager to define drill-ready targets and unlock the full potential of this underexplored VMS system.’

BUILDING ON A SERIES OF HIGH-GRADE DISCOVERIES

Recent prospecting has validated the Property’s critical mineral potential at multiple surface locations, including the MMZ and a newly identified northeast extension target. Results include a grab sample of 9.60% Zn, 1.56% Pb, 45.0 g/t Ag, and 0.57 g/t Au from the MMZ (see July 3, 2025 news release), and 2.17% Cu, 21.3 g/t Ag, and 0.22 g/t Au from angular float located along strike to the northeast of the MMZ in an undrilled area coincident with historical geophysical and soil anomalies (see June 16, 2025 news release). These sample locations are show on Figure 1.

STRATEGIC GOVERNMENT SUPPORT

Anteros’ Letter of Intent was approved under the JEA 2025 program as a Critical Minerals Primary Exploration Target, recognizing the Property’s alignment with provincial and federal priorities to secure domestic supplies of key metals. With up to $95,966 in non-dilutive funding already approved, this support significantly offsets early-stage costs while advancing shareholder value.

NEXT STEPS

Targeted trenching and channel sampling will continue at the Property into August. Pending results, the Company anticipates a Phase I drill program in Q3 2025 to test continuity and grade of the MMZ at shallow depths and along strike.

Figure 1: 2025 Grab Sample¹ Highlights at the Havens Steady Property

¹ Grab samples are selected samples and may not represent true underlying mineralization. Sample assay details, QA/QC procedures, and Qualified Person sign-off are available in the Company’s June 16 and July 3, 2025 news releases.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9885/260148_c121234a849089c6_002full.jpg

ABOUT THE PROPERTY

Located approximately 40 kilometres southeast of Buchans, the Havens Steady Property hosts a laterally extensive polymetallic volcanogenic massive sulphide (‘VMS’) system within the Storm Brook Formation of the Red Cross Group in the Exploits Subzone of the Dunnage Zone, a prolific metallogenic belt in central Newfoundland. The Property benefits from existing road infrastructure and proximity to hydroelectric power. The region hosts active exploration and world class VMS deposits including the past-producing Duck Pond Mine. The Company cautions that mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization on the Property.

Since acquiring the Property in January 2024, Anteros has compiled an extensive historical dataset that includes airborne electromagnetic surveys, geochemical surveys, and over 15,000 metres of historical drilling. Documented mineralization includes sphalerite, galena, chalcopyrite, and bornite in high-grade polymetallic zones. The known system has a strike length of over a kilometre and remains open at depth. Learn more: www.anterosmetals.com/havens-steady.

QUALIFIED PERSON

The technical content of this news release has been reviewed and approved by Jesse R. Halle, P.Geo., an independent Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

ABOUT Anteros Metals Inc.

Anteros is a multimineral junior mining company applying data science and geological expertise to identify and advance critical mineral opportunities in Newfoundland and Labrador. The Company is currently focused on advancing four key projects across diverse commodities and development horizons. Immediate plans for their flagship Knob Lake Property include bringing the historical Fe-Mn Mineral Resource Estimate into current status as well as commencing baseline environmental and feasibility studies.

Cautionary Statement Regarding Forward-Looking Information

This news release may contain ‘forward-looking information’ and ‘forward-looking statements’ within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements herein include but are not limited to statements relating to the prospects for development of the Company’s mineral properties, and are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260148

Allied Critical Metals Inc. (CSE: ACM,OTC:ACMIF) (OTCQB: ACMIF) (FSE: 0VJ0) (‘Allied’ or the ‘Company’), which is focused on its 100% owned past producing Borralha and Vila Verde tungsten projects in northern Portugal, is pleased to announce its listing on the OTCQB and the formation of its wholly owned U.S. subsidiary, Allied Critical Metals (USA), Inc. (‘Allied USA’), headquartered in Nashville, Tennessee. This strategic expansion marks a key milestone in ACM’s North American growth strategy and underscores its commitment to securing and supplying critical minerals to key U.S. industries.

United States Subsidiary

Allied USA will focus on the importation, marketing, and distribution of premium tungsten products across a range of sectors, including defense, aerospace, electronics, energy, and advanced manufacturing. Recognized for its exceptional hardness, density, and heat resistance, tungsten is essential to the development of high-performance technologies and national security applications.

‘We are proud to establish a dedicated U.S. subsidiary as we scale operations to meet rising domestic demand for strategic materials,‘ said Roy Bonnell, CEO of Allied Critical Metals. ‘The United States is a cornerstone market for tungsten, and Allied USA will allow us to serve our customers more directly with enhanced supply chain efficiency and superior product quality.’

The launch of Allied USA comes amid increasing interest in diversifying and securing domestic sources of critical minerals. With a focus on reliability, responsiveness, and technical excellence, Allied USA is positioned to become a trusted tungsten partner for U.S. manufacturers and government contractors.

Led by a team with deep industry expertise and strong market insight, Allied USA will prioritize building lasting customer relationships and ensuring the timely delivery of high-performance tungsten products across the country.

OTCQB Listing

Allied Critical Metals’ common shares are now trading in the United States on the OTCQB under the symbol ‘ACMIF’.

Roy Bonnell, CEO & Director commented, ‘Given the urgency to secure western sources of Tungsten and other critical metals, by the United States, securing an OTCQB listing was a priority for Allied. We expect U.S. investors will be a big part of the Company’s success as we move forward.’

To qualify for the OTCQB, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosures, and have a professional third-party sponsor introduction. OTCQB companies are distinguished by the integrity of their operations and the diligence with which they convey their qualifications.

U.S. investors can find current financial disclosures and real-time Level 2 quotes for the Company on www.otcmarkets.com/stock/ACMIF/overview.

DTC Eligibility

The Company is also pleased to announce that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (‘DTC’) in the United States. DTC eligibility simplifies the process of trading and enhances liquidity for U.S. investors by accelerating settlement times and reducing costs associated with trading shares.

DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC) that manages the electronic clearing and settlement of publicly traded companies. This eligibility provides a more streamlined process for investors and positions Allied to benefit from greater accessibility in the U.S. capital markets.

In addition, the Company has also entered into a financial advisory agreement dated June 20, 2025 as amended July 24, 2025 with Canaccord Genuity Corp. wherein it will provide financial advisory services in consideration for an advisory fee satisfied by the issuance of 1,200,000 common shares at a previously agreed effective price of $0.25 per share. The shares will be subject to a four month hold pursuant to the policies of the Canadian Securities Exchange and applicable securities laws.

About Allied Critical Metals Inc.

Allied Critical Metals Inc. (CSE: ACM,OTC:ACMIF) (OTCQB: ACMIF) (FSE: 0VJ0) is a Canadian-based mining company focused on the expansion and revitalization of its 100% owned past producing Borralha Tungsten Project and the Vila Verde Tungsten Project in northern Portugal. Tungsten has been designated a critical metal by the United States and other western countries, as they are aggressively seeking friendly sources of this unique metal. Currently, China, Russia and North Korea represent approximately 86% of the total global supply and reserves. The tungsten market is estimated to be valued at approximately USD $5 to $6 billion and it is used in a variety of industries such as defense, automotive, manufacturing, electronics, and energy.

Please visit our website at www.alliedcritical.com.

Also visit us at:
LinkedIn: https://www.linkedin.com/company/allied-critical-metals-inc 
X: https://x.com/@alliedcritical/
Instagram: https://www.instagram.com/alliedcriticalmetals/

ON BEHALF OF THE BOARD OF DIRECTORS

Per: ‘Roy Bonnell’

Roy Bonnell
Chief Executive Officer and Director

The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities of the Company have not been, nor will they be, registered under the 1933 Act or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act, as amended, and applicable state securities laws.

Cautionary Statement Regarding Forward-Looking Information

This news release contains ‘forward-looking statements’, including with respect to the use of proceeds. Wherever possible, words such as ‘may’, ‘would’, ‘could’, ‘should’, ‘will’, ‘anticipate’, ‘believe’, ‘plan’, ‘expect’, ‘intend’, ‘estimate’, ‘potential for’ and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the Company’s Listing Statement and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under the Company’s profile at www.sedarplus.ca ). Examples of forward-looking statements in this news release include, but are not limited to, statements regarding the proposed timeline and use of proceeds for exploration and development of the Company’s mineral projects as described in the Company’s Listing Statement, news releases, and corporate presentations. Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements and reference should also be made to the Company’s Listing Statement dated April 23, 2025 and news release dated May 16, 2025, and the documents incorporated by reference therein, filed under its SEDAR+ profile at www.sedarplus.ca for a description of additional risk factors. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260253

  Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3  

  On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25  

Radiopharm Theranostics (ASX: RAD,OTC:RDPTF, Nasdaq: RADX, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance of the Company’s Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody designed with strong affinity for the 4Ig isoform of B7H3 that is highly expressed in tumors and not in healthy tissues.

‘FDA clearance to initiate our first-in-human Phase 1 clinical trial of RV-01 represents a major milestone for Radiopharm Theranostics and our joint venture with MD Anderson Cancer Center,’ said Riccardo Canevari, CEO and Managing Director. ‘RV-01 is the first monoclonal antibody developed through this collaboration, and we believe it has the potential to become a highly differentiated radiopharmaceutical for patients with aggressive solid tumors. We are excited to advance this program into the clinic and anticipate dosing the first patients later this year.’

‘Recent reported preclinical studies demonstrated that RV-01 exhibits hepatic clearance, allowing the isotope sufficient time to effectively target tumors while potentially minimizing adverse effects such as hematological toxicities. Unlike peptides or small molecules, monoclonal antibodies are primarily cleared by the liver—an organ known for its radio-resistance. This characteristic, combined with the shortened half-life of RV-01 and the strong affinity for the target make this agent stand out and may offer a significant advantage not just over other monoclonal antibodies but also targeted radiotherapeutics with renal excretion pathway, the latter of which are often associated with higher risk of radiopharmaceutical-induced kidney toxicity,’ noted Dimitris Voliotis, M.D., Chief Medical Officer of Radiopharm Theranostics.

‘The high affinity and selectivity of RV-01 for the 4Ig isoform of B7H3 allows the antibody to bypass the soluble 2Ig isoform in the blood, boost binding of the radiopharmaceutical to tumor targets and avoid the formation of immune complexes in circulation,’ noted David Piwnica-Worms, M.D., Ph.D., Professor, MD Anderson Cancer Center, and scientific co-founder of Radiopharm Ventures.

B7-H3 is an immune checkpoint molecule that is overexpressed across several tumor types and has emerged as a compelling target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is consistently correlated with enhanced tumor aggressiveness and poor clinical outcomes. Targeting the 4 Ig isoform of B7-H3 with a selective radioligand therapy may offer a novel strategy for treating refractory or high-risk tumors.

  About RV-01  

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and MD Anderson Cancer Center (MDACC). RV-01 is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with RV-01 have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent. RV-01 has received IND-clearance from the U.S. FDA and plans to initiate a first-In-human Phase 1 study in the second half of 2025.

  About Radiopharm Theranostics  

 Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com .

  Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.  

  For more information:  

  Investors:  
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

  Media:  
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au  

  Follow Radiopharm Theranostics:  
Website – https://radiopharmtheranostics.com/  
X – https://x.com/TeamRadiopharm  
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/  
InvestorHub – https://investorhub.radiopharmtheranostics.com/